Atrial Fibrillation Duration and Cortical Lens Opacity

Predicting the Presence and Duration of Atrial Fibrillation From Cortical Lens Opacity

The prevalence of atrial fibrillation (AF) and the risk of stroke increase with a higher CHA2DS2-VASc score. Osmotic stress, which also contributes to cortical cataract formation, increases in the presence of diseases that raise the CHA2DS2-VASc score. Knowledge of AF duration is crucial because it heightens the risk of AF-related complications. This study investigated whether the presence of cortical cataracts, classified using the Lens Opacity Classification System (LOCS)stage, can predict the presence and duration of AF.

Study Overview

• Status: Completed
• Conditions: Atrial Fibrillation (AF); Cataract Cortical

Detailed Description

Atrial fibrillation (AF) is the most common type of heart rhythm disorder encountered in clinical settings and is associated with increased morbidity and mortality. The prevalence of AF and the risk of stroke increase with higher CHA2DS2-VASc scores . Cortical cataracts develop at the periphery of the lens and progress toward the center in a spoke-like pattern. The incidences of AF and cortical cataracts significantly increase with age .

Similar to subclinical AF, the initial onset of AF may go undetected, and the time required for AF to become permanent varies. Longer episodes of AF and higher CHA2DS2-VASc scores are strongly associated with an increased annual risk of stroke or systemic embolism , making it essential to estimate the duration of AF.

Cortical cataract stages can be easily identified and monitored through simple biomicroscopic examination. To our knowledge, no reliable method currently exists to predict the duration of AF of unknown onset. This study investigated the relationship between cortical cataract stages and the presence and duration of AF by analyzing p.osmolarity data and comparing it with the LAVI.

• Study Type: Observational
• Enrollment (Actual): 400

Contacts and Locations

Study Locations

• Turkey
  • Ankara, Turkey, 06530
    • Ankara Atatürk Sanatoryum TR Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

This study included 400 patients: 200 patients without AF (100 female, 100 male) and 200 patients with AF (100 female, 100 male). The patients' median age was 70 years. Patients with New York Heart Association class 1, 2, or 3 heart failure (HF) were included, regardless of the cause of HF.

Description

Inclusion Criteria:

Atrial Fibrillation patients

Exclusion Criteria:

Advanced HF (New York Heart Association class 4), Decompensated HF Prior cataract surgery Diabetic ketoacidosis Alcohol use Severe hyponatremia [sodium level of < 125 mEq/L], Nephrotic syndrome Cirrhosis Hypothyroidism

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort
group 1 ,group 2; The patients' median age was 70 years. Patients with New York Heart Association class 1, 2, or 3 heart failure (HF) were included, regardless of the cause of HF. Both groups comprised patients with a similar number and duration of comorbidities that contributed to their CHA2DS2-VASc scores.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
cortical cataract opacification grading.	All participants underwent detailed eye examinations using a biomicroscope . Digital photographs of the lenses were then captured using a smartphone under retro-illumination. Due to its simplicity, the Lens Opacity Classification System 2 [LOCS 2-Cortical] was used to perform cortical cataract opacification grading.	day1
LAVI (left atrial volume index)(ml/m2)	LAVI were measured using a GE Vivid N60 echocardiography system	day1

Collaborators and Investigators

• Sponsor: Ankara Ataturk Sanatorium Training and Research Hospital

Study record dates

Study Major Dates

• Study Start (Actual): July 1, 2017
• Primary Completion (Actual): March 1, 2024
• Study Completion (Actual): June 1, 2024

Study Registration Dates

• First Submitted: September 24, 2024
• First Submitted That Met QC Criteria: October 24, 2024
• First Posted (Actual): October 28, 2024

Study Record Updates

• Last Update Posted (Actual): October 28, 2024
• Last Update Submitted That Met QC Criteria: October 24, 2024
• Last Verified: October 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Cardiovascular Diseases; Pathologic Processes; Heart Diseases; Arrhythmias, Cardiac; Eye Diseases; Lens Diseases; Atrial Fibrillation; Cataract
• Other Study ID Numbers: AnkaraAtaturkSTRH

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Relationship between cortical cataract stages and the presence and duration of AF
• IPD Sharing Time Frame: 1-2 mounts
• IPD Sharing Access Criteria: All data generated in this study are available upon request from the corresponding authors except patient lens photographs.
• IPD Sharing Supporting Information Type: CSR

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No